1. Medtech Insight
  2. >>Device Area
  3. >>Cardiology

SCAI2018: New Study Shows 3D Printing Helps Prevent Leaks In Heart-Valve Patients

 
• By Marion Webb

The clinical use of 3D printing got a boost when interventional cardiologists presented data at the annual meeting of The Society for Cardiovascular Angiography and Interventions that supported th4 technology's effectiveness in helping to predict paravalvular leak in patients undergoing transcatheter aortic valve replacement. The implantation of an ill-fitting valve that can lead to paravalvular leak is a common risk of TAVR procedures.

Two female hands holding a 3d printed human heart

Data from a new study that evaluated the effectiveness of 3D printing and computer modeling in predicting paravalvular leak (PVL) in patients undergoing transcatheter aortic valve replacement (TAVR) has backed the use of the technology for addressing the problem of ill-fitting valves. The data was presented on April 26 at the 41st annual Society for Cardiovascular Angiography and Interventions (SCAI) meeting, which is being held in San Diego through April 28. 

In the study, six patients undergoing TAVR for severe calcific aortic stenosis and at risk for PVL had pre-procedure computed tomography (CT) images analyzed and segmented for printing of 3D...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiology

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By Marion Webb

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Digital Health And AI Tools Advance Cardiac Event Prediction, SCAI 2025 Data Show

 
• By Shubham Singh

Out-of-hospital cardiac arrest remains one of the most challenging and resource-intensive emergencies in cardiovascular care. At SCAI 2025, clinicians presented a novel algorithm that improved triage decisions and reduced unnecessary interventions.

Thousands Of Cardiac Digital Twins Reveal Novel Connections With Mental Health

 
• By Natasha Barrow

King’s College London, Imperial College London and The Alan Turing Institute constructed cardiac digital twins at scale, creating over 3,400, in a new study using UK Biobank data published in Nature Cardiovascular Research on 16 May.

More from Device Area

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By Marion Webb

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.